Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774009 | 0.91 | JAK2 (0.48) | MAPTKDM4EJAK2TRPV1JAK1 | |
| SCHEMBL5770812 | 0.89 | MAPT (0.48) | MAPTKDM4EJAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5775847 | 0.85 | RAB9A (0.52) | MAPTKDM4EJAK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6743436 | 0.83 | LMNA (0.44) | MAPTKDM4EJAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6647054 | 0.83 | TDP2 (0.52) | MAPTKDM4EJAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5774927 | 0.79 | NPC1 (0.42) | MAPTKDM4EJAK2POLBDGAT2 | |
| SCHEMBL5774131 | 0.79 | LMNA (0.53) | MAPTKDM4EJAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5774953 | 0.78 | LMNA (0.46) | MAPTKDM4EJAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5771367 | 0.78 | KDM4E (0.47) | MAPTKDM4EJAK2JAK1 | |
| SCHEMBL5777381 | 0.78 | GRM5 (0.46) | MAPTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436292-B1 | 5-METHOXY-8-ARYL-¬1,2,4|TRIAZOLO¬1,5-A|PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-08-30 | — | — | EP | claimed |
| EP-1436292-A1 | 5-METHOXY-8-ARYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | claimed |
| US-6693116-B2 | 8-PHENYL-(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2004-02-17 | — | — | US | claimed |
| US-20030134873-A1 | Adenosine receptor ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | claimed |
| WO-2003031445-A1 | 5-METHOXY-8-ARYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | claimed |
| EP-1436292-B1 | 5-METHOXY-8-ARYL-¬1,2,4|TRIAZOLO¬1,5-A|PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-08-30 | — | — | EP | disclosed |
| EP-1436292-A1 | 5-METHOXY-8-ARYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6693116-B2 | 8-PHENYL-(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030134873-A1 | Adenosine receptor ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | disclosed |
| WO-2003031445-A1 | 5-METHOXY-8-ARYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134873-A1 | Adenosine receptor ligands | ADORA1, ADORA2A, ADORA3 | MAPT 4867/4885KDM4E 4345/4885JAK2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.